BRAF and central nervous system cancer: The next speaker was Dr Abiola Ayanlaja, a post-doctoral research fellow (John Hopkins University, USA), who delivered a presentation on targeting SHP2-dependent adaptive resistance to BRAF and MEK inhibition in glioma.